-transparent.png){kind=logo}
Serum prostate-specific antigen (PSA) and prostatic acid phosphatase (PAP) levels were measured in 70 patients with benign prostatic hypertrophy (BPH) and in 70 patients with prostatic cancer. PSA was increased above the cutoff level of 10 ng/ml in 13% of patients with BPH and in 87% of patients with prostatic cancer. In contrast, abnormal PAP levels were found in 14 and 76% of patients, respectively. We concluded that, due to its high specificity, PSA is a useful marker in the management of patients with prostatic carcinoma and that it surpasses PAP in this regard.
Related Publications
X Filella, and
R Molina, and
J Jo, and
B Umbert, and
J L Bedini, and
A M Ballesta
January 1988,
American journal of clinical oncology,
X Filella, and
R Molina, and
J Jo, and
B Umbert, and
J L Bedini, and
A M Ballesta
January 1982,
International advances in surgical oncology,
X Filella, and
R Molina, and
J Jo, and
B Umbert, and
J L Bedini, and
A M Ballesta
December 1988,
British journal of urology,
X Filella, and
R Molina, and
J Jo, and
B Umbert, and
J L Bedini, and
A M Ballesta
January 1990,
The Journal of nuclear medicine and allied sciences,
X Filella, and
R Molina, and
J Jo, and
B Umbert, and
J L Bedini, and
A M Ballesta
January 1988,
The International journal of biological markers,
X Filella, and
R Molina, and
J Jo, and
B Umbert, and
J L Bedini, and
A M Ballesta
April 1986,
Medicina clinica,
X Filella, and
R Molina, and
J Jo, and
B Umbert, and
J L Bedini, and
A M Ballesta
February 1983,
The Journal of urology,
X Filella, and
R Molina, and
J Jo, and
B Umbert, and
J L Bedini, and
A M Ballesta
January 1988,
Urological research,
X Filella, and
R Molina, and
J Jo, and
B Umbert, and
J L Bedini, and
A M Ballesta
December 1986,
Urology,
X Filella, and
R Molina, and
J Jo, and
B Umbert, and
J L Bedini, and
A M Ballesta
January 1992,
Annals of clinical and laboratory science,
